119 patents
Utility
Interoperable platform for reducing redundancy in medical database management
16 Jan 24
Systems and methods are disclosed for reducing redundancy in medical database management.
Geoffrey Kim, Bobby Y. Reddy, Joel Choi Park, Rajuli Lall
Filed: 28 Mar 23
Utility
Treatment of Indolent or Aggressive B-cell Lymphomas Using a Combination Comprising BTK Inhibitors
11 Jan 24
Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody.
James HILGER, Xiaoping ZHANG, Shibao FENG, Sunhee RO, Jane HUANG
Filed: 15 Aug 23
Utility
Methods of Treating B-cell Proliferative Disorder
21 Dec 23
Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer.
Jason PAIK, Tommi SALMI, Ying OU
Filed: 31 May 23
Utility
Methods of Treating B-cell Proliferative Disorder
14 Dec 23
Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer.
Jason PAIK, Tommi SALMI, Ying OU
Filed: 6 Jun 23
Utility
Methods of Cancer Treatment Using Anti-TIGIT Antibodies in Combination with Anti-PD1 Antibodies
7 Dec 23
Provided are methods of treating cancer or increasing, enhancing, or stimulating an immune response with antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and antigen-binding fragments thereof in combination with an anti-PD1 antibody.
Tong Zhang, Liu Xue, Qi Liu, Min Wei, Kang Li, Yunxia Zuo
Filed: 20 Jan 22
Utility
Indoline Compounds and Derivatives As Egfr Inhibitors
23 Nov 23
Disclosed herein are novel pharmaceutically active compounds and their preparation methods.
Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
Filed: 22 Sep 21
Utility
3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE Compounds As HPK1 Inhibitor and Use Thereof
23 Nov 23
Sanjia XU, Jing LI, Zhiwei WANG
Filed: 29 Sep 21
Utility
Use of a Combination Comprising a BTK Inhibitor for Treating Cancers
16 Nov 23
A method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazo-lo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent.
Nan Hu, Lai WANG, Jing SONG, Tong ZHANG, Kang LI, Lusong LUO, Min WEI, Zhiwei WANG, Yunhang GUO
Filed: 23 May 23
Utility
Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
14 Nov 23
The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Zhiwei Wang, Yunhang Guo, Gongyin Shi
Filed: 6 Jul 22
Utility
Interleukin 15 Constructs and Methods of Use
9 Nov 23
Provided arm IL15 constructs, a pharmaceutical composition comprising said IL15 constructs, and use of the IL15 constructs or the composition for treating a disease, such as cancer, infectious disease or an immune disorder.
Xudong Luan, Xuesong Liu, Ming Lei
Filed: 16 Sep 21
Utility
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
17 Oct 23
Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-actyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody.
James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang
Filed: 29 Nov 18
Utility
Methods of treating B-cell proliferative disorder
17 Oct 23
Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer.
Jason Paik, Tommi Salmi, Ying Ou
Filed: 19 Jan 23
Utility
Degradation of Bruton's Tyrosine Kinase (BTK) by Conjugation of BTK Inhibitors with E3 Ligase Ligand and Methods of Use
12 Oct 23
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
Hexiang WANG, Bailin LEI, Changxin HUO, Dongqing SUN, Jie CHEN, Zhiwei WANG
Filed: 10 Mar 21
Utility
Imidazotriazine and Pyrrolopyrimidine Derivatives As Kras G12C Inhibitors
12 Oct 23
Disclosed herein are imidazotriazine and pyrrolopyrimidine derivatives or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a G12C inhibitors, and a pharmaceutical composition comprising the same.
Guoliang ZHANG, Jianzhuang MIAO, Ce WANG
Filed: 4 Aug 21
Utility
ANTI-PD1 Antibodies and Their Use As Therapeutics and Diagnostics
28 Sep 23
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Kang LI, Tong ZHANG, Jing SONG, Lanlan XU, Qi LIU, Hao PENG
Filed: 28 Apr 23
Utility
ANTI-PD-L1 Antibodies and Their Use As Therapeutics and Diagnostics
7 Sep 23
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
Kang LI, Jing SONG, Tong ZHANG, Yucheng LI, Zhiying REN, Yanshen KANG
Filed: 27 Oct 22
Utility
Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
15 Aug 23
Jing Li, Haibo Zhao, Zhiwei Wang
Filed: 8 Jul 21
Utility
Degradation of (Egfr) by Conjugation of Egfr Inhibitors with E3 Ligase Ligand and Methods of Use
10 Aug 23
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
Filed: 15 Jul 21
Utility
COMPOSITIONS COMPRISING (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE
3 Aug 23
The present invention relates to pharmaceutical compositions comprising (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for the treatment of B-cell malignancies.
Zhiwei WANG, Yunhang GUO, Gongyin SHI, Lai WANG
Filed: 7 Mar 23
Utility
Interoperable Platform for Reducing Redundancy In Medical Database Management
3 Aug 23
Systems and methods are disclosed for reducing redundancy in medical database management.
Geoffrey KIM, Bobby Y. REDDY, Joel Choi PARK, Rajuli Lall
Filed: 28 Mar 23